"On 23 July 2013, the US Food and Drug Administration (FDA), the Health and Environmental Sciences Institute (HESI) and the Cardiac Safety Research Consortium (CSRC) presented a new paradigm for cardiotoxicity testing, with a lofty goal of validating and standardizing the new assays in 2 years' time. A drastic change from current requirements, the proposal entails two non-clinical solutions: an in silico model that will probably integrate as many as six individual ion channel assays and electrophysiological tests on stem-cell-derived cardiomyocytes (Nature Rev. Drug Discov. 12, 565–567; 2013)."
Read the full article here: http://www.nature.com/nrd/journal/v12/n9/full/nrd4112.html